Cargando…

An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases

The objective of this review is to provide an update on narrowband ultraviolet B (NB-UVB) as a treatment for various skin conditions. NB-UVB works by suppressing the cutaneous cell-mediated immune response and has been shown to be an efficacious and clinically tolerable treatment for a range of infl...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Elisha, Kheradmand, Shiva, Miller, Richard
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634827/
https://www.ncbi.nlm.nih.gov/pubmed/34873522
http://dx.doi.org/10.7759/cureus.19182
_version_ 1784608192256278528
author Myers, Elisha
Kheradmand, Shiva
Miller, Richard
author_facet Myers, Elisha
Kheradmand, Shiva
Miller, Richard
author_sort Myers, Elisha
collection PubMed
description The objective of this review is to provide an update on narrowband ultraviolet B (NB-UVB) as a treatment for various skin conditions. NB-UVB works by suppressing the cutaneous cell-mediated immune response and has been shown to be an efficacious and clinically tolerable treatment for a range of inflammatory dermatoses. A literature search was conducted by advanced searches of PubMed for NB-UVB treatment of dermatologic skin diseases with a focus on reports from 2010 to 2021, including both office-based and home-based phototherapy (HBPT). Data were prioritized based on studies with a high level of evidence using the Oxford Evidence-Based Medicine guidance. We found that NB-UVB continues to serve as an effective form of therapy for several cutaneous conditions, including vitiligo, psoriasis, atopic dermatitis, mycosis fungoides, and other inflammatory dermatoses. The recent introduction of Janus kinase inhibitors in combination with NB-UVB suggests future promise in the treatment of vitiligo. Despite its rise in popularity, a decline was seen in office-based NB-UVB treatment during the coronavirus disease 2019 pandemic. Options are available to deliver NB-UVB at home with comparable efficacy to office-based treatments. In conclusion, for a select group of patients and conditions, NB-UVB continues to serve as an effective treatment modality with minimal side effects, with HBPT serving as an option to improve patient compliance.
format Online
Article
Text
id pubmed-8634827
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-86348272021-12-05 An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases Myers, Elisha Kheradmand, Shiva Miller, Richard Cureus Dermatology The objective of this review is to provide an update on narrowband ultraviolet B (NB-UVB) as a treatment for various skin conditions. NB-UVB works by suppressing the cutaneous cell-mediated immune response and has been shown to be an efficacious and clinically tolerable treatment for a range of inflammatory dermatoses. A literature search was conducted by advanced searches of PubMed for NB-UVB treatment of dermatologic skin diseases with a focus on reports from 2010 to 2021, including both office-based and home-based phototherapy (HBPT). Data were prioritized based on studies with a high level of evidence using the Oxford Evidence-Based Medicine guidance. We found that NB-UVB continues to serve as an effective form of therapy for several cutaneous conditions, including vitiligo, psoriasis, atopic dermatitis, mycosis fungoides, and other inflammatory dermatoses. The recent introduction of Janus kinase inhibitors in combination with NB-UVB suggests future promise in the treatment of vitiligo. Despite its rise in popularity, a decline was seen in office-based NB-UVB treatment during the coronavirus disease 2019 pandemic. Options are available to deliver NB-UVB at home with comparable efficacy to office-based treatments. In conclusion, for a select group of patients and conditions, NB-UVB continues to serve as an effective treatment modality with minimal side effects, with HBPT serving as an option to improve patient compliance. Cureus 2021-11-01 /pmc/articles/PMC8634827/ /pubmed/34873522 http://dx.doi.org/10.7759/cureus.19182 Text en Copyright © 2021, Myers et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Dermatology
Myers, Elisha
Kheradmand, Shiva
Miller, Richard
An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases
title An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases
title_full An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases
title_fullStr An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases
title_full_unstemmed An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases
title_short An Update on Narrowband Ultraviolet B Therapy for the Treatment of Skin Diseases
title_sort update on narrowband ultraviolet b therapy for the treatment of skin diseases
topic Dermatology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8634827/
https://www.ncbi.nlm.nih.gov/pubmed/34873522
http://dx.doi.org/10.7759/cureus.19182
work_keys_str_mv AT myerselisha anupdateonnarrowbandultravioletbtherapyforthetreatmentofskindiseases
AT kheradmandshiva anupdateonnarrowbandultravioletbtherapyforthetreatmentofskindiseases
AT millerrichard anupdateonnarrowbandultravioletbtherapyforthetreatmentofskindiseases
AT myerselisha updateonnarrowbandultravioletbtherapyforthetreatmentofskindiseases
AT kheradmandshiva updateonnarrowbandultravioletbtherapyforthetreatmentofskindiseases
AT millerrichard updateonnarrowbandultravioletbtherapyforthetreatmentofskindiseases